Global Antidepressants Market Overview
Antidepressants are drugs utilized in the treatment of depressive disorders such as dysthymia, anxiety, obsessive-compulsive disorder, eating disorders, chronic pain, and neuropathic pain. Depression is a medical illness that is associated with the brain. Symptoms of depression include lacking energy, feeling sad and tired, and having trouble in enjoying routine daily activities. As per data published by CDC, depression affects around 1 in every 5 individuals in the U.S. According to WHO (World Health Organization), at present around 350 million people are affected by depression across the world. Depression affects about 10% to 25% of women and 10% to 15% men. The antidepressant market accounted for US$ 13.2 billion in 2019 and is estimated to be US$ 26.1 billion by 2029 and is anticipated to register a CAGR of 7.1%.
Impact of COVID-19 on the market
The antidepressant market has triggered during the COVID-19 outbreak. The growing number of cases and fatalities is distressing mental health by elevating anxiety across the world. People who are already experiencing mental health problems are facing increased stress levels over the Covid-19 outbreak. This has surged the demand for antidepressant drugs.
Global Antidepressants Market Dynamics
Rising cases of depression
Depression mostly occurs due to the factors, such as stressful work environment and social isolation which has to lead the most toward the growing number of people suffering from depression. The number of people falling victim to depression and related disorders is projected to continue to rise, as a result of stressful work schedule due to technology, indecorous eating habits, increasing isolation from family and loved ones, and the lack of ability to adapt to the fast pace, at which, the world is moving forward. In countries, such as the United States and the United Kingdom, which are categorized by their rapid-paced economies, the percentage of the 'affected population' is quite high in every age group. As per the Office for National Statistics 2017, 1 in every 4 people in the United Kingdom are victim depression. Thus, the growing cases of depression are projected to propel the overall growth of the market studied across the world during the forecast period.
Side-effects and patent expiry
The antidepressants are Celexa (citalopram) and Lexapro (escitalopram), both of which are used to treat depression. Lexapro also helps to treat anxiety. Celexa and Lexapro can cause side effects mutual to others which include sleeplessness, nausea, dry mouth, sweating, and drowsiness. Celexa and Lexapro can also have serious side effects including excessive bleeding, vision issues, and seizures. In 2018, the tags of the medications contained a black warning box due to growth in suicide risk. Thus, the side-effects and patent expiry of antidepressants drugs are projected to hamper the growth of the antidepressants market.
Global Antidepressants Market Segmentation
The Antidepressants market is segmented based on the product, depressive disorder, and region.
On the basis of the product, the Antidepressants market is segmented into selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), a tricyclic Antidepressants (TCA), monoamine oxidase inhibitor (MAOI), and other products. Based on the depressive disorder, the target market is segmented into major depressive disorder, obsessive-compulsive disorder (OCD), and generalized anxiety disorder (GAD), panic disorder (PD), and other depressive disorders.
Regional Insights:
In the region, the antidepressants market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America Antidepressants market is the most leading market, owing to the presence of a large patient population suffering from various types of depression and anxiety disorders. Nevertheless, in the U.S. the Antidepressants market is currently saturated, as various Antidepressants drugs are available on prescription in the market. Furthermore, market maturity, loss of patent exclusivity, shortened drug lifecycles, and generic infiltration are the factors that contribute to the decline of the market growth in the region. The Asia Pacific is anticipated to register considerable growth due to several factors such as the high occurrence of psychiatric disorders and rapid economic growth in countries such as China, Japan, and Australia. Moreover, optimistic marketing approval for innovative medicines is likely to boost the target market over the forecast period.
|
Attribute |
Details |
|
The base year for estimation |
2019 |
|
Forecast period |
2019 – 2029 |
|
Market representation |
Revenue in USD Million & CAGR from 2019 – 2029 |
|
Market Segmentation |
By Product - Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-norepinephrine Reuptake Inhibitor (SNRI), Tricyclic Antidepressants (TCA), Monoamine Oxidase Inhibitor (MAOI), and Other Products By Depressive Disorder - Major Depressive Disorder, Obsessive-compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD), Panic Disorder (PD), and Other Depressive Disorders |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the Antidepressants market report based on product, depressive disorder, and region.
Antidepressants Market, By Product:
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Serotonin-norepinephrine Reuptake Inhibitor (SNRI)
- Tricyclic Antidepressants (TCA)
- Monoamine Oxidase Inhibitor (MAOI)
- Other Products
Antidepressants Market, By Depressive Disorder:
- Major Depressive Disorder
- Obsessive-compulsive Disorder (OCD)
- Generalized Anxiety Disorder (GAD)
- Panic Disorder (PD)
- Other Depressive Disorders
Antidepressants Market, By Region:
- North America
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
-
- U.S.
- Canada
- Middle East & Africa
Global Antidepressants Market Key Players
The key players operating in the antidepressants market include Allergan Plc, Alkermes Plc, Bristol Myers Squibb Co., Eli Lilly and Co., Lundbeck A/S, GlaxoSmithKline Plc, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd. Prominent players are focusing on expanding distribution networks as well as expanding geographical presence, as the Asia Pacific, the Middle East& Africa, and Latin America are developing regions with the improving economic conditions and the growing occurrence of various types of depressive disorders. For instance, in May 2018, Allergan, an Ireland based company, focused on developing, manufacturing, and commercializing branded pharmaceutical, biologic, device, surgical, and regenerative medicine products for patients around the world acquired Aptinyx for an unclosed amount. Aptinyx, a clinical-stage biopharmaceutical company focused on the discovery and development of transformative therapies for challenging neurologic disorders. Through this acquisition, Allergan gained important insights into NMDA receptor modulation as a potential therapeutic approach for depression.
Global Antidepressants Market Company Profile
- Allergan Plc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Alkermes Plc
- Bristol Myers Squibb Co.
- Eli Lilly and Co.
- Lundbeck A/S
- GlaxoSmithKline Plc
- Merck & Co., Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
“*” marked represents similar segmentation in other categories in the respective section
Global Antidepressants Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Preview
- Executive Summary
- Key Findings—Global Outlook for Antidepressants Strategies
- Key Questions this Study will Answer
- Market Snippet, By Product
- Market Snippet, By Depressive Disorder
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Market Segmentation, By Product, 2019 – 2029, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Serotonin-norepinephrine Reuptake Inhibitor (SNRI)
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Tricyclic Antidepressant (TCA)
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Monoamine Oxidase Inhibitor (MAOI)
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Other Products
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Overview
- Market Segmentation, By Depressive Disorder, 2019 – 2029, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- Major Depressive Disorder
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Obsessive-compulsive Disorder (OCD)
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Generalized Anxiety Disorder (GAD)
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Panic Disorder (PD)
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Other Depressive Disorders
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Overview
- Global Market, By Region, 2019 – 2029, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Regional Trends
- North America
- Market Size and Forecast (US$ Bn), By Product, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Depressive Disorder, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Bn), By Product, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Depressive Disorder, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Bn), By Product, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Depressive Disorder, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Bn), By Product, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Depressive Disorder, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Bn), By Product, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Depressive Disorder, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- Allergan Plc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Alkermes Plc
- Bristol Myers Squibb Co.
- Eli Lilly and Co.
- Lundbeck A/S
- GlaxoSmithKline Plc
- Merck & Co., Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Allergan Plc
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
The Antidepressants market is segmented based on the product, depressive disorder, and region.
In 2018, the tags of the medications contained a black warning box due to growth in suicide risk. Thus, the side-effects and patent expiry of antidepressants drugs are projected to hamper the growth of the antidepressants market.
In the region, the antidepressants market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America Antidepressants market is the most leading market, owing to the presence of a large patient population suffering from various types of depression and anxiety disorders. Nevertheless, in the U.S. the Antidepressants market is currently saturated, as various Antidepressants drugs are available on prescription in the market.
The key players operating in the antidepressants market include Allergan Plc, Alkermes Plc, Bristol Myers Squibb Co., Eli Lilly and Co., Lundbeck A/S, GlaxoSmithKline Plc, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd.